Nicholas Vogelzang
Hematology & Oncology · Las Vegas, NVNPI 1558361154
Payments from drug & device makers
Across 1,711 payments — averaging $4829.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4.3M
- Genentech, Inc.$667K
- Astrazeneca UK Limited$587K
- Clovis Oncology, Inc.$275K
- Bayer$274K
- Eisai Inc.$271K
- plus $1.8M from 38 others
Across 10 payments — averaging $1200.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
- Pfizer$4K
- Onquality Pharmaceuticals (USA) LLC$998
- F. Hoffmann-la Roche AG$739
- Macrogenics, Inc.$606
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,262,762 in reported general payments places this provider in the 95th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Edwin KingsleyLas Vegas$9.2M
- Oscar GoodmanLas Vegas$6M
- Khawaja JahangirLas Vegas$2.5M
- Carolyn MulroneyLas Vegas$1.5M
- Wolfram SamlowskiLas Vegas$1.1M
- Anuradha ThummalaLas Vegas$736K
- Grzegorz ObaraLas Vegas$668K
- Aaron GoodmanLas Vegas$480K
- Vikas GuptaLas Vegas$300K
- Clark JeanLas Vegas$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.